BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 21463120)

  • 1. Sunitinib in relapsed or refractory diffuse large B-cell lymphoma: a clinical and pharmacodynamic phase II multicenter study of the NCIC Clinical Trials Group.
    Buckstein R; Kuruvilla J; Chua N; Lee C; Macdonald DA; Al-Tourah AJ; Foo AH; Walsh W; Ivy SP; Crump M; Eisenhauer EA
    Leuk Lymphoma; 2011 May; 52(5):833-41. PubMed ID: 21463120
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II evaluation of sunitinib in the treatment of recurrent or refractory high-grade glioma or ependymoma in children: a children's Oncology Group Study ACNS1021.
    Wetmore C; Daryani VM; Billups CA; Boyett JM; Leary S; Tanos R; Goldsmith KC; Stewart CF; Blaney SM; Gajjar A
    Cancer Med; 2016 Jul; 5(7):1416-24. PubMed ID: 27109549
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma.
    Robertson MJ; Kahl BS; Vose JM; de Vos S; Laughlin M; Flynn PJ; Rowland K; Cruz JC; Goldberg SL; Musib L; Darstein C; Enas N; Kutok JL; Aster JC; Neuberg D; Savage KJ; LaCasce A; Thornton D; Slapak CA; Shipp MA
    J Clin Oncol; 2007 May; 25(13):1741-6. PubMed ID: 17389337
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase II and pharmacodynamic study of sunitinib in relapsed/refractory oesophageal and gastro-oesophageal cancers.
    Wu C; Mikhail S; Wei L; Timmers C; Tahiri S; Neal A; Walker J; El-Dika S; Blazer M; Rock J; Clark DJ; Yang X; Chen JL; Liu J; Knopp MV; Bekaii-Saab T
    Br J Cancer; 2015 Jul; 113(2):220-5. PubMed ID: 26151457
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II trial of sunitinib in patients with relapsed or refractory germ cell tumors.
    Feldman DR; Turkula S; Ginsberg MS; Ishill N; Patil S; Carousso M; Bosl GJ; Motzer RJ
    Invest New Drugs; 2010 Aug; 28(4):523-8. PubMed ID: 19547919
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of hematologic toxicities in cancer patients treated with sunitinib: a systematic review and meta-analysis.
    Funakoshi T; Latif A; Galsky MD
    Cancer Treat Rev; 2013 Nov; 39(7):818-30. PubMed ID: 23455076
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I study of sunitinib plus bevacizumab in advanced solid tumors.
    Rini BI; Garcia JA; Cooney MM; Elson P; Tyler A; Beatty K; Bokar J; Mekhail T; Bukowski RM; Budd GT; Triozzi P; Borden E; Ivy P; Chen HX; Dolwati A; Dreicer R
    Clin Cancer Res; 2009 Oct; 15(19):6277-83. PubMed ID: 19773375
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation.
    Carr LL; Mankoff DA; Goulart BH; Eaton KD; Capell PT; Kell EM; Bauman JE; Martins RG
    Clin Cancer Res; 2010 Nov; 16(21):5260-8. PubMed ID: 20847059
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II study of sunitinib malate in head and neck squamous cell carcinoma.
    Choong NW; Kozloff M; Taber D; Hu HS; Wade J; Ivy P; Karrison TG; Dekker A; Vokes EE; Cohen EE
    Invest New Drugs; 2010 Oct; 28(5):677-83. PubMed ID: 19649772
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.
    Rini BI; Michaelson MD; Rosenberg JE; Bukowski RM; Sosman JA; Stadler WM; Hutson TE; Margolin K; Harmon CS; DePrimo SE; Kim ST; Chen I; George DJ
    J Clin Oncol; 2008 Aug; 26(22):3743-8. PubMed ID: 18669461
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial.
    Younes A; Berdeja JG; Patel MR; Flinn I; Gerecitano JF; Neelapu SS; Kelly KR; Copeland AR; Akins A; Clancy MS; Gong L; Wang J; Ma A; Viner JL; Oki Y
    Lancet Oncol; 2016 May; 17(5):622-31. PubMed ID: 27049457
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I study of safety and tolerability of sunitinib in combination with sirolimus in patients with refractory solid malignancies and determination of VEGF (VEGF-A) and soluble VEGF-R2 (sVEGFR2) in plasma.
    Li J; Kluger H; Devine L; Lee JJ; Kelly WK; Rink L; Saif MW
    Cancer Chemother Pharmacol; 2016 Jun; 77(6):1193-200. PubMed ID: 27103123
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II study of sunitinib in patients with relapsed or refractory small cell lung cancer.
    Han JY; Kim HY; Lim KY; Han JH; Lee YJ; Kwak MH; Kim HJ; Yun T; Kim HT; Lee JS
    Lung Cancer; 2013 Feb; 79(2):137-42. PubMed ID: 23182663
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II open label study of the oral vascular endothelial growth factor-receptor inhibitor PTK787/ZK222584 (vatalanib) in adult patients with refractory or relapsed diffuse large B-cell lymphoma.
    Brander D; Rizzieri D; Gockerman J; Diehl L; Shea TC; Decastro C; Moore JO; Beaven A
    Leuk Lymphoma; 2013 Dec; 54(12):2627-30. PubMed ID: 23488610
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I study of sunitinib combined with modified FOLFOX6 in patients with advanced solid tumors.
    Leong S; Eckhardt SG; Chan E; Messersmith WA; Spratlin J; Camidge DR; Diab S; Khosravan R; Lin X; Chow Maneval E; Lockhart AC
    Cancer Chemother Pharmacol; 2012 Jul; 70(1):65-74. PubMed ID: 22623210
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I and pharmacokinetic study of sunitinib in pediatric patients with refractory solid tumors: a children's oncology group study.
    Dubois SG; Shusterman S; Ingle AM; Ahern CH; Reid JM; Wu B; Baruchel S; Glade-Bender J; Ivy P; Grier HE; Adamson PC; Blaney SM
    Clin Cancer Res; 2011 Aug; 17(15):5113-22. PubMed ID: 21690570
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sunitinib in patients with metastatic renal cell carcinoma.
    Motzer RJ; Rini BI; Bukowski RM; Curti BD; George DJ; Hudes GR; Redman BG; Margolin KA; Merchan JR; Wilding G; Ginsberg MS; Bacik J; Kim ST; Baum CM; Michaelson MD
    JAMA; 2006 Jun; 295(21):2516-24. PubMed ID: 16757724
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Maintenance Sunitinib following Initial Platinum-Based Combination Chemotherapy in Advanced-Stage IIIB/IV Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study-CALGB 30607 (Alliance).
    Baggstrom MQ; Socinski MA; Wang XF; Gu L; Stinchcombe TE; Edelman MJ; Baker S; Feliciano J; Novotny P; Hahn O; Crawford JA; Vokes EE
    J Thorac Oncol; 2017 May; 12(5):843-849. PubMed ID: 28161554
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma.
    Grivas PD; Daignault S; Tagawa ST; Nanus DM; Stadler WM; Dreicer R; Kohli M; Petrylak DP; Vaughn DJ; Bylow KA; Wong SG; Sottnik JL; Keller ET; Al-Hawary M; Smith DC; Hussain M
    Cancer; 2014 Mar; 120(5):692-701. PubMed ID: 24249435
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase II study of 2-methoxyestradiol nanocrystal colloidal dispersion alone and in combination with sunitinib malate in patients with metastatic renal cell carcinoma progressing on sunitinib malate.
    Bruce JY; Eickhoff J; Pili R; Logan T; Carducci M; Arnott J; Treston A; Wilding G; Liu G
    Invest New Drugs; 2012 Apr; 30(2):794-802. PubMed ID: 21174224
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.